OncLive News Network: On Location at ASCO 2021 - Episode 1

Lung Cancer and Leukemia Recap at ASCO 2021: Drs Ed Kim and Anthony Mato

Gina Mauro
Gina Mauro

Editorial Director, OncLive
Gina Mauro is your lead editorial contact for OncLive. She joined the company in 2015 and has held various positions on OncLive; she is also the on-air correspondent for OncLive News Network: On Location. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

,
Anthony R. Mato, MD, MSCE

,
Edward S. Kim, MD

OncLive sits down with Edward S. Kim, MD, and Anthony R. Mato, MD, on the pivotal studies in lung cancer and leukemia at the 2021 ASCO Annual Meeting.

Today-

We are reporting from the 2021 ASCO Annual Meeting!

We are highlighting some of the top news presented each day during the meeting—and soon we’ll speak with Dr. Ed Kim to discuss some new data in lung cancer, and Dr. Anthony Mato to recap some top findings in leukemia.

Welcome to OncLive News Network! I’m Gina Mauro.

In non–small cell lung cancer, updated findings from the phase 2 CodeBreaK100 trial showed that totorasib provided continued durable clinical benefit in patients with pretreated KRAS p.G12C–mutated disease.

Amivantamab combined with lazertinib elicited responses in more than one third of chemotherapy-naïve patients with EGFR-mutant non–small cell lung cancer who had progressed on osimertinib, according to data from a cohort of the CHRYSALIS trial.

Nivolumab and ipilimumab plus 2 cycles of platinum-based chemotherapy demonstrated a durable survival benefit vs chemotherapy alone in patients with advanced non–small cell lung cancer, as seen in the 2-year follow-up analysis of the phase 3 CheckMate 9LA trial.

In the phase 2 SPEARHEAD-1 trial, encouraging initial durability has been observed with afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

A single infusion of the CAR T-cell therapy brexucabtagene autoleucel demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia, as seen in the ZUMA-3 trial.

In acute lymphoblastic leukemia, phase 2 data demonstrated with the combination of ponatinib and blinatumomab represent a potentially promising chemotherapy-free, hematopoietic stem cell transplant —sparing treatment for patients with Philadelphia chromosome–positive disease.

Please be sure to check out more of our coverage from the 2021 ASCO Annual Meeting.

That’s all for today. Catch us tomorrow, where we will sit down with Dr Milind Javle to discuss the latest in gastrointestinal cancers, as well as Dr Erika Hamilton to speak about some top breast cancer studies.

Thank you for watching OncLive News Network: On Location, I’m Gina Mauro.